Drug Profile
Cergutuzumab amunaleukin - Roche
Alternative Names: CEA-IL-2v; RG-7813; RO-6895882Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Roche
- Class Antineoplastics; Immunoglobulins; Interleukins; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Carcinoembryonic antigen inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Dec 2019 Roche completes a phase I trial in Solid tumours (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA, Canada, Denmark, Netherlands, Spain and Switzerland (IV) (NCT02350673)
- 12 Feb 2019 Roche terminates phase I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Canada, Denmark, Netherlands, Spain and Switzerland (IV) (Roche pipeline, February 2019)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Solid-tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Switzerland, Spain, Netherlands, Denmark, Canada, USA (IV, Infusion)